Metabolic-Fit / 100
Willow review
Unusually open about its clinicians and pharmacies — a named CMO, roughly forty-five named physicians, three named compounding pharmacies — and unusually loose about its advertising, having dropped 'comparable to FDA-approved semaglutide' claims only after the National Advertising Division referred it to the FTC.
- HSA / FSA-eligible
- Editor-vetted
- No insurance needed
Referral link, walled off from the score
Elena Voss is a mother writing for mothers, not a treating clinician, and holds no medical license. Every clinical figure in this piece is cited inline to its primary source — the trial or the FDA label — so you can open it and check us. This is background reading, not medical advice.
Willow at a glance
- Semaglutide
- From $299/mo
- Tirzepatide
- From $399/mo
- Coverage
- 36 states
- Brand-name
- Compounded only
How we scored Willow
Each factor is scored from Willow's real pricing, disclosures and oversight, then combined into the 66/100 Metabolic-Fit Score by the same weighted six-factor framework we apply to every provider — never nudged by whether a provider pays us.
No postpartum or breastfeeding framing — a generic weight program.
Thin on the hormonal picture that drives many mothers' weight.
Limited public detail on who oversees care and how.
Cost is unpredictable or sits at the premium end.
Support is thin once the prescription ships.
Complaints cluster around billing lock-in and hard cancellation.
How we verified this review
- Last verified
- July 2026
- Confidence
- medium
- Primary source
- www.startwillow.com/faqs
Operating entity is Willow Health Services, Inc. (Austin, TX; Florida telehealth registration TPME1718); the medical practice is a separate entity, Willow Medical of California, P.C. Prices are posted publicly per product with no quiz: semaglutide injection and sublingual tablets $299/mo, tirzepatide injection and sublingual tablets $399/mo, NAD+ $199. No intro or first-month price exists anywhere on Willow's own site — the '$249 first month' figure circulating on review sites is third-party only and UNVERIFIED. PRICING SCALES WITH DOSE: the Terms state the fee 'may be increased or decreased if your prescription changes, such as by a dosage increase', so the flat-$299 claim on other review sites is wrong. STATE COVERAGE RESOLVED at 36 states, listed verbatim in Willow's FAQ. Reconciling against affiliate-network materials: the network's 18-state exclusion list is WRONG on four — Maine, Massachusetts, Tennessee and Wyoming are all served, confirmed both in the FAQ list and by walking the live state gate, which advanced for all four while bouncing Alabama, Mississippi and New Mexico to an unsupported-state page. Conversely the network implies DC is available; Willow does not serve DC. Compounding pharmacies ARE named (Red Rock Home, Epiq, The Pharmacy Hub), as is a CMO (Dr. Michael Green, MD) and ~45 physicians. No LegitScript seal, no 503A/503B language, no lab work anywhere. ⚠ REGULATORY: two findings, both attaching to Willow Health Services, Inc. and NOT to the unrelated Willow breast-pump company. (1) NAD case #7488 — on a Novo Nordisk challenge, BBB National Programs' National Advertising Division recommended on 4 Dec 2025 that Willow modify or discontinue superiority, safety and efficacy claims for its compounded semaglutide; Willow REFUSED, and NAD referred the matter to the FTC, state Attorneys General and the ad platforms. On 24 July 2026 — one week before this review — Willow returned to NAD after discussion with the FTC and voluntarily discontinued the claims, including that its products were 'comparable to FDA-approved semaglutide products' and delivered weight loss 'without diet or exercise'. (2) Eli Lilly v. Willow Health Services (C.D. Cal.), a Lanham Act suit over compounded tirzepatide marketing, was DISMISSED WITH PREJUDICE on 3 Feb 2026 — an outcome favourable to Willow, and reported here for balance. NOT VERIFIED: the FDA warning-letter database was not queryable, so 'no FDA letter' is search-based only, not a confirmed negative; Willow has NO BBB profile at all, so its lack of BBB complaints is not a clean record; Trustpilot (354 reviews) returned 403.
What to expect when you sign up
We walked Willow's public signup funnel (July 2026) — a first-hand look at the flow. We don't create accounts, enter medical data, or complete checkout, so this is what any visitor sees, not a patient outcome.
- 1Every price is public on its own product page — no quiz, no email gate, no account needed
- 2Step 1 of the funnel asks your state from a dropdown listing all 50; there is no warning beforehand that Willow serves only 36, and unsupported states are bounced to a waitlist page only after you submit
- 3Supported states move to name and personal details, then a health-history form — 'you'll share your health, lifestyle, and medical history in a short online form'
- 4A licensed physician reviews the form asynchronously and, if eligible, prescribes; Willow advertises same-day approval, which only an async review makes possible
What we noticed
- Pricing is NOT flat: the Terms state the fee 'may be increased or decreased if your prescription changes, such as by a dosage increase', and the FAQ hedges that 'medication costs vary by dosage and prescription' — the flat-$299 claim circulating on review sites is not supported by Willow's own documents
- Three compounding pharmacies ARE named in the Terms — Red Rock Home Pharmacy (UT), Epiq Pharmacy (TX) and The Pharmacy Hub (FL) — with addresses and phone numbers, which is well above average disclosure
- A named Chief Medical Officer (Dr. Michael Green, MD) and roughly forty-five individually named physicians with bio pages — most competitors on this roster name nobody
- Three DIFFERENT cancellation windows appear across three Willow pages: 'at least 2 business days' in the FAQ, 'two (2) full calendar days' in the Terms, and refunds only 'within 24 hours of order placement' in the Informed Consent
- Labs and bloodwork are never mentioned anywhere on the site — not included, not offered, not required — and there is no coaching or dietitian benefit
- The Terms are dated 11.24.2021 and still describe the business as 'women's health services', and the cancellation contact URL they point to is dead
Pricing
Prices re-verified
| Medication | Plan | Monthly |
|---|---|---|
| Compounded semaglutide | InjectionPosted publicly at /compound-semaglutide, no quiz required. A semaglutide + B12 blend is offered at the same $299. Treat it as a STARTING price: the Terms say the fee 'may be increased or decreased if your prescription changes, such as by a dosage increase'. | $299 |
| Compounded tirzepatide | InjectionPosted publicly at /compound-tirzepatide. Also dose-scaled rather than flat. | $399 |
| Oral semaglutide | Sublingual tablet, needle-freePosted at /semaglutide-tablets — a daily under-the-tongue tablet at the same price as the injection. | $299 |
| Oral tirzepatide | Sublingual tablet, needle-freePosted at /tirzepatide-tablets. Note Willow's own FAQ says the oral option is 'Semaglutide only', contradicting this live product page — one of several internal inconsistencies on the site. | $399 |
HSA/FSA is commonly accepted for GLP-1 telehealth — check your plan. Prices reflect Willow's public disclosures at last review and change often; confirm the current number on Willow's own site.
What we like
- Both molecules offered as sublingual tablets as well as injections — a genuinely uncommon menu
- Names a Chief Medical Officer and roughly forty-five individual physicians with bio pages, plus three compounding pharmacies with addresses — far more disclosure than most of this roster
- Every price is posted publicly per product, with no quiz, email gate or account required
- The plan price bundles medication, the medical evaluation, unlimited physician messaging and free shipping, with no additional fees stated
The caveats
- Dropped claims that its compounded semaglutide was 'comparable to FDA-approved' products and produced weight loss 'without diet or exercise' only after the National Advertising Division referred it to the FTC and state attorneys general
- The fee scales with your dose — $299 and $399 are starting prices, and no per-dose table is published anywhere
- Three different cancellation windows appear across three of its own pages: two business days, two calendar days, and 24 hours from order
- Available in 36 states, but the signup form offers all fifty and only rejects you after you submit
- No lab work is mentioned anywhere on the site, and there is no coaching or dietitian benefit
- Its Terms are dated 2021, still describe the business as 'women's health services', and point cancellations at a dead URL
- Sublingual GLP-1 tablets are far less studied than the injectables the pivotal trials used
- Breastfeeding appears only as an exclusion criterion, and there is no postpartum content at all
Willow for mothers: our verdict
Unusually open about its clinicians and pharmacies — a named CMO, roughly forty-five named physicians, three named compounding pharmacies — and unusually loose about its advertising, having dropped 'comparable to FDA-approved semaglutide' claims only after the National Advertising Division referred it to the FTC. It runs about $299/month — a premium to the category, so the extras have to earn it.
We weigh Willow the way mothers actually have to: not just the monthly cost, but postpartum and breastfeeding timing and PCOS and insulin resistance — the parts a generic weight-loss review skips.
What Willow actually costs
- Compounded semaglutide — Injection: $299/mo
- Compounded tirzepatide — Injection: $399/mo
- Oral semaglutide — Sublingual tablet, needle-free: $299/mo
- Oral tirzepatide — Sublingual tablet, needle-free: $399/mo
For context, the typical ongoing price across our roster is around $199/month, so Willow sits at the premium end.
The medications Willow prescribes
Willow prescribes semaglutide and tirzepatide — the two molecules with the strongest published weight-loss outcomes, and having both on one account matters when insulin resistance (common with PCOS and after gestational diabetes) makes tirzepatide the better-suited option. These are compounded formulations from a licensed pharmacy — the reason the price stays down — but compounded GLP-1s aren't FDA-approved finished products the way Wegovy and Zepbound are.
A needle-free oral or sublingual option is on the menu, which draws in mothers who've been avoiding injections — just set expectations: oral and buccal delivery of these peptides is far less studied than the injectable versions the trials used.
Where Willow fits — and where it doesn't — for mothers
A good fit if…
- you may need to move between semaglutide and tirzepatide as your body and hormones change.
Look elsewhere if…
- you specifically want an FDA-approved brand pen with its own pregnancy and lactation labeling.
- you want frictionless cancellation — the fine print here is where the complaints cluster.
- you'd rather a prescriber talk through timing around postpartum and breastfeeding timing — that's what our #1 pick, CoreAge Rx, is built for.
Trust, safety, and oversight
Our confidence is moderate — the core facts check out, but some details (per-state availability, program mechanics) aren't fully public. As with any compounded GLP-1, the most useful thing mothers can do is confirm which licensed pharmacy fills the prescription and what's in the formulation — we explain how we weigh oversight in our scoring methodology.
A standing caveat for mothers: GLP-1 medications aren't established as safe during pregnancy or breastfeeding, and every label advises against use. Nothing here changes that — plan the timing with your own clinician.
The bottom line
Willow is a reasonable option — weigh it on postpartum and breastfeeding timing and PCOS and insulin resistance against the alternatives below. For most mothers, CoreAge Rx remains the stronger all-round fit — see why it tops our ranking.
The bottom line for mothers
Best for: Mothers in one of its 36 states who want a sublingual GLP-1 rather than a weekly injection, value knowing exactly which doctor and which pharmacy are behind the prescription, and will get the price at their target dose in writing.
Alternatives to Willow
Providers we have a referral relationship with, ordered by their Metabolic-Fit Score — highest first. This module leaves out the provider whose page you are reading, so on CoreAge Rx's own review our #1 pick is the one name you will not find here. These are not the whole roster: see the full ranking for every provider we cover, paid or not.
- Visit CoreAge Rx92
Metabolic-Fit / 100
CoreAge RxOur #1 pickOne flat price, both molecules on a single chart, and a prescriber who reads your history before writing — the most predictable place for a mother to start and, just as important, to pause.
- Visit Gala Health84
Metabolic-Fit / 100
A flat $179 for either molecule with a genuinely gentle microdosing tier — a reasonable, all-doses-included option if you can live with a yearly plan and a pharmacy it doesn't name.
- Visit Enhance MD82
Metabolic-Fit / 100
One of the more oversight-forward compounded programs here — lab work and a live provider visit bundled into a mid-tier flat price, with a gentle microdosing tier — which is exactly what you want when thyroid and hormones are already in flux.
Keep comparing Willow
Head-to-head & alternatives
Willow, answered
- Does Willow really offer GLP-1 tablets instead of injections?
- Yes — Willow sells sublingual semaglutide and tirzepatide tablets on their own product pages, alongside the usual injections. For a mother who has been putting this off because of the needle, that is a real reason to look. Set expectations honestly, though: these are compounded sublingual formulations, and that route is far less studied than the weekly injection the pivotal trials used, so the published outcome numbers do not automatically carry over.
- What does Willow actually cost per month?
- Semaglutide is $299 a month and tirzepatide $399, injection or sublingual tablet, all posted openly without a quiz — which is more transparency than most of this market offers. The catch is that these are starting prices. Willow's Terms say the fee 'may be increased or decreased if your prescription changes, such as by a dosage increase', and its FAQ adds that costs 'vary by dosage and prescription'. So the flat-$299-at-every-dose claim you may have read elsewhere is not what Willow's own documents say. No per-dose table is published, and there is no intro or first-month rate on its site. Get your target dose quoted in writing.
- Is Willow available in my state?
- Willow lists 36 states in its FAQ. Worth knowing before you start: the signup form opens with a dropdown of all fifty, with no warning about limits — enter an unsupported state and you are bounced to a waitlist page after submitting. One note if you are comparing sources: some affiliate directories carry an 18-state exclusion list for Willow that is wrong on four. Maine, Massachusetts, Tennessee and Wyoming are all served — we confirmed that both in Willow's published list and by walking the live state gate. Washington DC, which those directories imply is available, is not served.
- Has Willow been in trouble over its advertising?
- Yes, and it is recent enough that you should know. After a challenge by Novo Nordisk, the National Advertising Division recommended in December 2025 that Willow drop or modify safety and efficacy claims for its compounded semaglutide. Willow refused, and NAD referred the matter to the FTC and state attorneys general. In July 2026 Willow returned to NAD following discussion with the FTC and voluntarily dropped the claims — including that its products were comparable to FDA-approved semaglutide and produced weight loss without diet or exercise. In fairness, this concerns marketing language rather than any finding about the medication, and a separate Eli Lilly suit against Willow was dismissed with prejudice in February 2026. But a company that had to be walked to the FTC before withdrawing 'no diet or exercise' claims is telling you something about how it sells.
- Does Willow handle postpartum or breastfeeding timing?
- No. Willow states it is available to adults who are 'not pregnant or breastfeeding' — that is an exclusion, not guidance — and it publishes nothing on postpartum care at all. There is a single PCOS article and no PCOS programme behind it. The practical points still apply: semaglutide's labeling asks for a two-month stop before a planned pregnancy, tirzepatide carries no such washout, and the injectable labels do not prohibit breastfeeding — they record that there are no human-milk data and ask you and your clinician to weigh it. If timing around nursing is your real question, a provider whose clinicians will discuss it fits better.
Pricing, states and verification reflect Willow's public disclosures at last review; the Metabolic-Fit Score is our editorial judgment per the published methodology. This is background reading, not medical advice — GLP-1 medications are not established as safe in pregnancy or breastfeeding. See our medical disclaimer and how we're funded.